Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 9/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 12/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383101 | 0.86 | KDR (0.67) | KDRKITFLT3PDGFRB | |
| SCHEMBL1383479 | 0.84 | KDR (0.70) | KDRKITFLT3PDGFRB | |
| SCHEMBL5253141 | 0.84 | KDR (0.70) | KDRKITPDGFRAFLT3PDGFRB | |
| SCHEMBL1383493 | 0.84 | KDR (0.72) | KDRKITFLT3PDGFRB | |
| SCHEMBL4736063 | 0.84 | KDR (0.70) | KDRKITFLT3PDGFRB | |
| SCHEMBL422402 | 0.84 | KIT (0.74) | KDRKITFLT3 | |
| SCHEMBL4740220 | 0.82 | KDR (0.72) | KDRALDH1A1KITFLT3PDGFRB | |
| SCHEMBL4736486 | 0.82 | KDR (0.72) | KDRKITPDGFRAFLT3PDGFRB | |
| SCHEMBL4738714 | 0.82 | KDR (0.63) | KDRKITPDGFRAFLT3PDGFRB | |
| SCHEMBL1382612 | 0.82 | KDR (0.68) | KDRKITFLT3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008080110-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | ALCON, INC. (CH) | 2008-07-03 | — | — | WO | claimed |
| EP-1850839-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON INC. (CH) | 2007-11-07 | — | — | EP | claimed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | claimed |
| EP-1850839-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON INC. (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | disclosed |